Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors
Background/Aim. Kidney tumors account for 2–3% of all tumors. Renal cell carcinoma (RCC) is the tenth most common malignancy. Sunitinib is used as the first treatment line in patients with a good and intermediate prognosis. The aim of this study was to analyze the risk factors, frequency, and advers...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
2021-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84502000145M.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850214490337968128 |
|---|---|
| author | Mugoša Snežana Džamić Zoran Sahman-Zaimović Majda Lukovac-Janjić Nevenka |
| author_facet | Mugoša Snežana Džamić Zoran Sahman-Zaimović Majda Lukovac-Janjić Nevenka |
| author_sort | Mugoša Snežana |
| collection | DOAJ |
| description | Background/Aim. Kidney tumors account for 2–3% of all tumors. Renal cell carcinoma (RCC) is the tenth most common malignancy. Sunitinib is used as the first treatment line in patients with a good and intermediate prognosis. The aim of this study was to analyze the risk factors, frequency, and adverse drug reactions (ADRs) of sunitinib in patients with metastatic RCC. Methods. The retrospective study included 170 patients treated at the Clinic for Oncology of the Clinical Center of Montenegro, Urology Clinic of the Clinical Center of Serbia, and Clinic for Oncology of the Clinical Center Niš. As a data source, we used patient medical histories and/or electronic patient records. ADRs were characterized by using Rawlins and Thompson classification. Each ADRs severity was assessed in accordance with the World Health Organization criteria. Causality was assessed using the Naranjo probability scale. Results. ADRs of sunitinib occurred in 152 (89.4%) patients. ADRs were 89% type A and 11% type C. Disorders of the blood and lymphatic system, gastrointestinal disorders, and disorders of the skin and subcutaneous tissue were the most common manifestations of ADRs of sunitinib. Causality assessment was most commonly classified as certain (60%). Serious ADRs occurred in 4.5% of patients. Most patients recovered without consequences. The most common manifestations of ADRs were: leukopenia, hypothyroidism, thrombocytopenia, diarrhea, stomatitis, asthenia, and hypertension. All ADRs were expected. The number of concomitant medications and the duration of therapy proved to be the most significant risk factors for ADR to sunitinib. Conclusion. Our study shows that the incidence of ADRs of sunitinib in patients with kidney cancer is high. The ADRs were mostly moderate and mild in intensity and occurred as a consequence of the pharmacological action of the drug. It is necessary to conduct continuous education of medical oncologists in the field of monitoring safe drug use, as well as patients on sunitinib therapy, in order to improve their awareness of the sunitinib ADRs and the risk factors that lead to them, with the aim of reducing their frequency. |
| format | Article |
| id | doaj-art-80e441ad4dd14cd282bbe0283f8ca5ca |
| institution | OA Journals |
| issn | 0042-8450 2406-0720 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj-art-80e441ad4dd14cd282bbe0283f8ca5ca2025-08-20T02:08:53ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502406-07202021-01-0178445646110.2298/VSP201109145M0042-84502000145MAdverse drug reactions associated with sunitinib therapy: Characteristics and risk factorsMugoša Snežana0Džamić Zoran1Sahman-Zaimović Majda2Lukovac-Janjić Nevenka3University of Montenegro, Faculty of Medicine, Podgorica, Montenegro + Institute for Medicines and Medical Devices, Podgorica, MontenegroUniversity of Belgrade, Faculty of Medicine, Clinic for Urology, Belgrade, SerbiaUniversity of Montenegro, Faculty of Medicine, Podgorica, Montenegro + Institute for Medicines and Medical Devices, Podgorica, MontenegroUniversity of Montenegro, Institute for Oncology and Radiotherapy, Podgorica, MontenegroBackground/Aim. Kidney tumors account for 2–3% of all tumors. Renal cell carcinoma (RCC) is the tenth most common malignancy. Sunitinib is used as the first treatment line in patients with a good and intermediate prognosis. The aim of this study was to analyze the risk factors, frequency, and adverse drug reactions (ADRs) of sunitinib in patients with metastatic RCC. Methods. The retrospective study included 170 patients treated at the Clinic for Oncology of the Clinical Center of Montenegro, Urology Clinic of the Clinical Center of Serbia, and Clinic for Oncology of the Clinical Center Niš. As a data source, we used patient medical histories and/or electronic patient records. ADRs were characterized by using Rawlins and Thompson classification. Each ADRs severity was assessed in accordance with the World Health Organization criteria. Causality was assessed using the Naranjo probability scale. Results. ADRs of sunitinib occurred in 152 (89.4%) patients. ADRs were 89% type A and 11% type C. Disorders of the blood and lymphatic system, gastrointestinal disorders, and disorders of the skin and subcutaneous tissue were the most common manifestations of ADRs of sunitinib. Causality assessment was most commonly classified as certain (60%). Serious ADRs occurred in 4.5% of patients. Most patients recovered without consequences. The most common manifestations of ADRs were: leukopenia, hypothyroidism, thrombocytopenia, diarrhea, stomatitis, asthenia, and hypertension. All ADRs were expected. The number of concomitant medications and the duration of therapy proved to be the most significant risk factors for ADR to sunitinib. Conclusion. Our study shows that the incidence of ADRs of sunitinib in patients with kidney cancer is high. The ADRs were mostly moderate and mild in intensity and occurred as a consequence of the pharmacological action of the drug. It is necessary to conduct continuous education of medical oncologists in the field of monitoring safe drug use, as well as patients on sunitinib therapy, in order to improve their awareness of the sunitinib ADRs and the risk factors that lead to them, with the aim of reducing their frequency.http://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84502000145M.pdfdrug-related side effects and adverse reactionskidney neoplasmssunitinib |
| spellingShingle | Mugoša Snežana Džamić Zoran Sahman-Zaimović Majda Lukovac-Janjić Nevenka Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors Vojnosanitetski Pregled drug-related side effects and adverse reactions kidney neoplasms sunitinib |
| title | Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors |
| title_full | Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors |
| title_fullStr | Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors |
| title_full_unstemmed | Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors |
| title_short | Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors |
| title_sort | adverse drug reactions associated with sunitinib therapy characteristics and risk factors |
| topic | drug-related side effects and adverse reactions kidney neoplasms sunitinib |
| url | http://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84502000145M.pdf |
| work_keys_str_mv | AT mugosasnezana adversedrugreactionsassociatedwithsunitinibtherapycharacteristicsandriskfactors AT dzamiczoran adversedrugreactionsassociatedwithsunitinibtherapycharacteristicsandriskfactors AT sahmanzaimovicmajda adversedrugreactionsassociatedwithsunitinibtherapycharacteristicsandriskfactors AT lukovacjanjicnevenka adversedrugreactionsassociatedwithsunitinibtherapycharacteristicsandriskfactors |